CHICAGO, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced that it has added Tom Kolefas to its Advisory Board. Kolefas brings more than 25 years of Wall Street experience on the buyside - managing both mutual fund and institutional equities at TIAA Investments, Jennison Associates, Loomis Sayles, Mackay-Shields and Bank of New York; as well as industry experience as a chemical engineer and corporate development officer at Engelhard/BASF. The Company looks forward to benefiting from his experience in the capital markets, his expertise on what investors in different sectors and investment strategies look for, and his outstanding relationships in the investment management space. “Tom Kolefas brings a wealth of expertise to our company,” said Grigorios Siokas, Chief Executive Officer of Cosmos Holdings. “He has a track record for success in identifying value within the mid-cap space. We look forward to his contribution as we position ourselves for continued growth.” "I am excited to be advising the team at Cosmos Holdings under the dynamic leadership of Gregory Siokas as it grows as a company,” said Tom Kolefas. “Cosmos has a well-thought out, balanced strategy of organic growth, market share gains, new product introductions and acquisitions to capitalize on the growth in the drug, nutraceutical, vitamin and Europe-only cannabis end-markets in Europe, the U.S. and ultimately, the rest of the world." About Cosmos Holdings, Inc. Cosmos Holdings Inc. is an international pharmaceutical company focused on identifying, acquiring, developing, and commercializing medicines to improve patients' lives and outcomes. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece & in Harlow, UK. More information is available at www.cosmosholdingsinc.com. FORWARD LOOKING STATEMENTS Except for historical information, this news release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve unknown risks, and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Important factors that might cause such differences are discussed in the Company's filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results could differ materially from those anticipated in these forward-looking statements, if new information becomes available in the future.